Treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) does not appear to be associated with serious adverse outcomes in adults hospitalised with influenza, according to findings of a Danish study published in *JAMA Network Open*.

Danish registry-based study, which included all patients 40 years of age or over who were hospitalised with influenza or influenza-related pneumonia in Danish hospitals between 2010 and 2018, assessed the association between current NSAID use (prescribed within 60 days preadmission) and the risk of admission to an intensive care unit (ICU), death within 30 days, and pleuropulmonary infections including empyema and lung abscess.

Overall, 6.7% of the 7747 patients with confirmed influenza had received NSAIDs.

In unmatched cohorts, the risk of ICU admission was significantly higher in current NSAID users than in non-users (20.0% vs 13.3%; relative risk \[RR\] 1.51; 95% CI 1.26, 1.81), but the risk of death within 30 days was similar (7.1% vs 7.8%; RR 0.91; 95% CI 0.66, 1.26).

In propensity score match cohorts with influenza, the risk of ICU admission was not significantly increased in NSAID users versus non-users (RR 1.25; 95% CI 0.95, 1.63) and the risk of death was not increased (RR 1.03; 95% CI 0.66, 1.60). However, use of NSAIDs significantly increased the risk of pleuropulmonary infections (RR 2.13; 95% CI 1.63, 2.77).

\"NSAID use was not associated with a clinically significant increased risk of ICU admission or death in patients hospitalized with influenza. While studies on the association of NSAIDs with the disease course of COVID-19 are clearly needed, the currently available data, including the present study, do not seem to support strong recommendations against using NSAIDs in patients with viral pneumonia,\" said the investigators.
